Showing 2601-2610 of 7279 results for "".
- New Tapinarof Data Promising for Children and Perhaps Morehttps://practicaldermatology.com/news/New-Tapinarof-Data-Promising-Children-Perhaps-More/2471623/An analysis of the Phase 3 ADORING 3 study evaluating tapinarof cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD) presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, demonstrated that AD disease activity re
- Research Letter: Molecule Enhances Skin Barrier, Reduces Retinoid Side Effectshttps://practicaldermatology.com/news/research-letter-molecule-enhances-skin-barrier-reduces-retinoid-side-effects/2471610/A formulation containing Epicutis Skincare’s proprietary TSC molecule significantly reduced erythema and dryness caused by tretinoin, according to a research letter published in the Journal of Cosmetic Dermatology.
- Journey Medical's Claude Maraoui to Speak in 'Fireside Chat' at ROTH Conferencehttps://practicaldermatology.com/news/Journey-Medicals-Claude-Maraoui-Speak-Fireside-Chat-ROTH-Conference/2471608/Journey Medical Corporation president and CEO Claude Maraoui will participate in a “fireside chat” Tuesday, March 18, at the 37th Annual ROTH Conference in Dana Point, California, the company announced. Maraoui’s session will be held at 12:30 p.m. PT, and a webcast will be available for ap
- New Spesolimab Data Indicate Impact on Both Physical, Mental Healthhttps://practicaldermatology.com/news/New-Spesolimab-Data-Indicate-Impact-Both-Physical-Mental-Health/2471581/New analyses of the effects of spesolimab on the physical symptoms and mental health burden associated with generalized pustular psoriasis (GPP) were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. These post-hoc exploratory analyses from the
- Biologics, JAKs, and More Cited as Potential Treatments for CPUOhttps://practicaldermatology.com/news/Biologics-JAKis-More-Cited-Potential-Treatments-CPUO/2471552/New therapies for chronic pruritus of unknown origin (CPUO) could be close, Gil Yosipovitch, MD, said during his presentation, “What’s Best and What’s Next for Systemic Itch and CPUO” at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “These are patients
- Evolving Approaches to Treating Melasma Highlighted at AADhttps://practicaldermatology.com/news/Evolving-Approaches-Treating-Melasma-Highlighted-AAD/2471546/Use of imaging and aggressive treatment are critical in the medical management of melasma in 2025, Mukta Bhardwaj Sachdev,MD, IFAAD, said at the 2025 American Academy of Dermatology (AAD) Annuel Meeting in Orlando, Florida. “You need to use imaging systems, monitor your patients, [use] top
- Martha Stewart Describes Neurotoxin Preferenceshttps://practicaldermatology.com/news/martha-stewart-describes-neurotoxin-preferences/2471541/BOTOX Cosmetic’s platysma bands indication has a fan in Martha Stewart. The keynote speaker at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, said she visits her dermatologist “once every couple months.” Gesturing to her jaw and neck, Stewart said she ge
- Molluscum Contagiosum: Old Condition, Same Challengeshttps://practicaldermatology.com/news/molluscum-contagiosum-old-condition-same-challenges/2471528/Molluscum contagiosum has been studied and treated for almost two centuries, and while modern therapies are helping patients obtain better outcomes, some aspects of managing and treating the disease remain challenging At the 2025 American Academy of Dermatology (AAD) Annual Meeting, Dr. Ad
- IPC Comorbidities Symposium Covers Depression, Obesity, and Morehttps://practicaldermatology.com/news/IPC-Comorbidities-Symposium-Covers-Depression-Obesity-More/2471517/Comorbidities of psoriasis were the focus of the International Psoriasis Council’s meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “Syposium: Preventing Comorbig Disease in Psoriasis” started with presentations on depression and card
- Analysis: Nicotinamide Not Linked to Elevated MACE Riskhttps://practicaldermatology.com/news/study-nicotinamide-not-linked-to-mace-risk/2471380/Results from a new retrospective cohort study suggest nicotinamide exposure was not associated with an increased risk of major adverse cardiovascular events (MACE). The analysis included data from 13,108 patients in the Vanderb